Genetic test identifies patients with triple negative breast cancer who are unlikely to respond to immunotherapies
by European Organisation for Research and Treatment of CancerProfessor Laura van 't Veer presented latest results from the I-SPY2 phase 2 clinical trial at the 14th European Breast Cancer Conferen
Updated on: March 30,2024
Genetic test identifies patients with triple negative breast cancer who are unlikely to respond to immunotherapies
by European Organisation for Research and Treatment of CancerProfessor Laura van 't Veer presented latest results from the I-SPY2 phase 2 clinical trial at the 14th European Breast Cancer Conferen
Updated on:March 30,2024
